Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, B-2160 Antwerp, Belgium.
Int J Mol Sci. 2022 Aug 29;23(17):9795. doi: 10.3390/ijms23179795.
Dry eye disease (DED) is a multifactorial disorder that leads to ocular discomfort, visual disturbance, and tear film instability. DED is accompanied by an increase in tear osmolarity and ocular surface inflammation. The diagnosis and treatment of DED still present significant challenges. Therefore, novel biomarkers and treatments are of great interest. Proteases are present in different tissues on the ocular surface. In a healthy eye, proteases are highly regulated. However, dysregulation occurs in various pathologies, including DED. With this review, we provide an overview of the implications of different families of proteases in the development and severity of DED, along with studies involving protease inhibitors as potential therapeutic tools. Even though further research is needed, this review aims to give suggestions for identifying novel biomarkers and developing new protease inhibitors.
干眼症（DED）是一种多因素疾病，可导致眼部不适、视觉障碍和泪膜不稳定。DED 伴有泪液渗透压升高和眼表面炎症。DED 的诊断和治疗仍然存在很大的挑战。因此，新型生物标志物和治疗方法受到了广泛关注。蛋白酶存在于眼表面的不同组织中。在健康的眼睛中，蛋白酶受到高度调节。然而，在包括 DED 在内的各种病理情况下，这种调节会发生紊乱。通过这篇综述，我们概述了不同蛋白酶家族在 DED 的发生和严重程度中的作用，并介绍了涉及蛋白酶抑制剂作为潜在治疗工具的研究。尽管还需要进一步的研究，但本综述旨在为确定新型生物标志物和开发新型蛋白酶抑制剂提供建议。
